Multi-dimensional Fragmentomic Assay for Early Detection of Pancreatic Neuroendocrine Tumors

Launched by FUDAN UNIVERSITY · Apr 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new method to detect pancreatic neuroendocrine tumors (a type of tumor that affects the pancreas) early using a blood test. Researchers want to see how well this test can identify these tumors by analyzing small pieces of DNA found in the blood. Early detection is important because it can lead to better treatment options and outcomes for patients.

To be eligible for the trial, participants must be at least 18 years old and have a confirmed diagnosis of a pancreatic neuroendocrine tumor before undergoing surgery. They should not have received any cancer treatments like chemotherapy or radiation before joining the study. Participants will need to provide blood samples and follow the research guidelines, but they can expect to receive support and information throughout the process. This trial is currently recruiting, and anyone interested should discuss with their healthcare provider to see if they qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 and above, regardless of gender;
• • Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor or gastrointestinal neuroendocrine tumor before surgery;
• • Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
• • No obvious surgical contraindications;
• • Able to comply with research plans, follow-up plans, and other protocol requirements;
• • Voluntary participation and signed informed consent.
• Exclusion Criteria:
• • Pathological diagnosis was not a neuroendocrine tumor;
• • Currently diagnosed with other types of tumors or any cancer history;
• • Diagnosed with familial syndromes;
• • Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
• • Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw;
• • Recipient of blood transfusion within 30 days prior to study blood draw;
• • Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;
• • Poor health condition and not suitable for blood draw;
• • Any other disease/condition deemed not suitable for study enrollment by researcher.